Navigation Links
Cutanea Announces Promising Phase II Results in Rosacea with Omiganan
Date:10/17/2007

Plans to Move Forward with Phase III

MALVERN, Pa., Oct. 17 /PRNewswire/ -- Cutanea Life Sciences, an emerging specialty pharmaceutical company focused on improving human health and appearance through the development and commercialization of treatments for diseased and aging skin conditions, today announced results from its completed Phase II clinical trial of Omiganan.

The trial compared Omiganan 2.5% and 1% topical gel to vehicle in subjects with papulopustular rosacea. Study results demonstrated that the formulation was safe and well-tolerated at all doses tested. Among the once-daily treatment arms, a dose-dependent response was observed in both lesion reductions and Treatment Success, as defined by Investigator Global Assessment (IGA) scores. After nine weeks of treatment, once-daily (QD) Omiganan 2.5% gel showed superior lesion count reductions and Treatment Success, compared to 1% Omiganan QD and vehicle. Omiganan provided greater improvements compared to vehicle among patients with a more severe condition at Baseline (more numerous inflammatory lesions). Lesion counts continued to drop at all evaluations over the duration of the study, indicating that further improvements may be expected with a duration of treatment exceeding nine weeks. Twice daily (BID) application of 2.5% Omiganan did not demonstrate substantial improvement in lesion reduction or the number of patients reaching Treatment Success compared to once daily application. Based on the results from this study, Cutanea has selected a once-daily dose of Omiganan 2.5% for further development for the treatment of papulopustular rosacea.

Dr. Guy Webster, Founding and Current President of the American Acne & Rosacea Society and Clinical Professor of Dermatology at Jefferson Medical College stated, "Topical Omiganan is a novel approach, actually the first in a new class of dermatologic drugs, for the treatment of rosacea. Initial results are promising and I look f
'/>"/>

SOURCE Cutanea Life Sciences
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... NEW YORK , Aug. 1, 2014 ... Square Capital Management, L.P. today responded to the filing ... AGN ) in California.  The complaint makes baseless ... offer rules.  Allergan,s true purpose in ... shareholders, efforts to call a special meeting.  That purpose ...
(Date:8/1/2014)... Aug. 1, 2014 In the latest call ... sexual dysfunction, more than 60 doctors and leading medical ... letter questioning the Food and Drug Administration,s (FDA) decision ... form of male sexual dysfunction compared with ZERO for ... to act for women by approving the first-ever drug ...
(Date:8/1/2014)... Aug. 1, 2014 In the latest call ... sexual dysfunction, more than 60 doctors and leading medical ... letter questioning the Food and Drug Administration,s (FDA) decision ... form of male sexual dysfunction compared with ZERO for ... to act for women by approving the first-ever drug ...
Breaking Medicine Technology:Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 660+ Healthcare Professionals Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Healthcare Professionals Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 360+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3
... Reportlinker.com announces that a new market research report ... Drug Markets in Europe ... and the strategies of major pharmaceutical companies ... in Europe remains problematic for the developers, although ...
... Urban League (NUL) and the League of United Latin American ... negotiations and come to an agreement with Walgreens on new ... Americans, especially in diverse and underserved communities, stand to lose ... In an open letter to Express Scripts, Marc H. ...
Cached Medicine Technology:Orphan Drug Markets in Europe 2Orphan Drug Markets in Europe 3Orphan Drug Markets in Europe 4Orphan Drug Markets in Europe 5Orphan Drug Markets in Europe 6Orphan Drug Markets in Europe 7The National Urban League and League of United Latin American Citizens Urge Express Scripts to Reach Agreement with Walgreens 2The National Urban League and League of United Latin American Citizens Urge Express Scripts to Reach Agreement with Walgreens 3
(Date:8/1/2014)... News) -- The U.S. Food and Drug Administration announced ... to help fight type 2 diabetes. Jardiance ... treatment regimens to control blood sugar levels in the ... the Office of Drug Evaluation II in the FDA,s ... agency statement. The FDA also recommended that Jardiance ...
(Date:8/1/2014)... 01, 2014 The evolving healthcare ... community pharmacies. At ThoughtSpot 2014, AmerisourceBergen and Good ... practices and resources to enhance patient care and ... on critical issues to give independent pharmacists the ... , ThoughtSpot show attendance experienced a nearly ...
(Date:8/1/2014)... 01, 2014 Growing prevalence of ... healthcare reforms are boosting healthcare market growth, although ... discounts and increasing generic consumption is a major ... million in 2013, having grown at a Compound ... The implementation of the Health Transformation Program (Saglikta ...
(Date:8/1/2014)... with the progressive, deadly respiratory ailment known as chronic ... battle the disease, the U.S. Food and Drug Administration ... treatment, an inhaled spray called Striverdi Respimat (olodaterol) for ... is often linked to smoking, involves multiple lung conditions ... with COPD may experience a number of symptoms, such ...
(Date:8/1/2014)... Abington, PA (PRWEB) August 01, 2014 ... beneficial than bottle-feeding. A recent study conducted ... may not lag too far behind in terms of ... simply want to know what’s best for their baby. ... , According to Dr. Steven Shapiro , chair ...
Breaking Medicine News(10 mins):Health News:FDA Approves New Type 2 Diabetes Drug 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 2Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 3Health News:Turkey Pharmaceutical and Medical Device Market Worth $21.5B & $3.3B by 2020 Respectively, Says a Report Available at MarketOptimizer.org 4Health News:FDA Approves New Treatment for People With COPD 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 2Health News:Despite Recent Study, Abington Health Expert Encourages Breastfeeding 3
... Flight West (AFW),awarded The Distinguished Pilot award to Oakland ... September 29th. Birely completed,37 Angel Flight West missions over ... in need whose non-emergency health care problems require that,they ... AFW volunteer,pilots, donates the cost of all the missions ...
... and audio web cast on October 9, 2007 --, BELLEVILLE, ON, Oct. 5 /PRNewswire-FirstCall/ - ... Agriculture,(USDA) comment on a field trial for its E. coli O157:H7 cattle vaccine,during a: ... Conference Call & Audio Web Cast ... Tuesday, October 9, 2007 ...
... National Center for Complementary and Alternative Medicine (NCCAM) ... Research on Complementary and Alternative Medicine (CAM) to ... the biological effects of a number of plant-derived ... as dietary supplements, on pancreatic diseases, autoimmune and ...
... oncology tests, SAN DIEGO, Oct. 5 AviaraDx, ... a corporate overview of its molecular,diagnostic test offerings and ... is scheduled for Thursday, November,1st, at 2:30 p.m. in ... Marriott,Del Mar Hotel, 11966 El Camino Real, San Diego, ...
... Texans?, AUSTIN, Texas, Oct. 5 AARP today ... of TXU amounts,to one more backroom deal that ignores ... billion in new debt for a mere,one-time $15 electric ... said Bob Jackson, AARP Texas,state director. "They,ll be the ...
... aren,t consuming recommended levels, experts say , , FRIDAY, Oct. ... officials warned pregnant women to eat no more than ... mercury contamination, many women have been confused, and fish ... says that that warning by the U.S. Food and ...
Cached Medicine News:Health News:Angel Flight West Recognizes Northern California Pilots at AFW 24th Anniversary Awards 2Health News:NCCAM expands Centers of Excellence in CAM research program 2Health News:NCCAM expands Centers of Excellence in CAM research program 3Health News:AARP Calls on State Regulators to Reject Proposed Settlement of TXU Buyout 2Health News:Fish Safe for Pregnant Women to Eat 2Health News:Fish Safe for Pregnant Women to Eat 3
... offers a complete line of flowmeters, available in oxygen, ... available in a variety of calibrations to best suit ... to the gas in use, the Amvex Flowmeter is ... the U with I. For Power Take-Off add PT ...
... Amvex offers a complete line of flowmeters, available in ... all available in a variety of calibrations to best ... specific to the gas in use, the Amvex Flowmeter ... replace the U with I. For Power Take-Off add ...
... complete line of flowmeters, available in oxygen, air, heliox ... a variety of calibrations to best suit your application. ... gas in use, the Amvex Flowmeter is a user ... with I. For Power Take-Off add PT to the ...
0-3.5 LPM Oxygen Flowmeter with Ohmeda male inlet...
Medicine Products: